Get access

The role of additional radiotherapy for primary central nervous system lymphoma (PCNSL)

  • Protocol
  • Intervention

Authors

  • Jonas Zacher,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Bettina Schmidtke,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Benjamin Kasenda,

    1. University Hospital Basel, Institute for Clinical Epidemiology and Biostatistics, Basel, Basel, Switzerland
    Search for more papers by this author
  • Andreas Engert,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Nicole Skoetz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. nicole.skoetz@uk-koeln.de.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objectives of this review are to assess and summarise the evidence on efficacy and adverse events of radiotherapy in the treatment of immunocompetent patients with PCNSL with respect to overall survival (OS), progression-free survival (PFS), response, adverse events (AE), treatment-related mortality (TRM) and quality of life (QoL).

Get access to the full text of this article